Physicians should encourage pharmaceutical companies to make socially responsible funding decisions and take an active role in setting biomedical research priorities by advocating for fair and effective allocations of public and private biomedical R & D investments.
A Canadian physician reports there is systematic bias to the outcome of published research funded by the pharmaceutical industry and believes more steps need to be taken to improve the integrity of clinical research reports in the United States and Canada.
Dr Oluwole Jegede joins Ethics Talk to discuss his article, coauthored with Drs Julio C. Nunes, Terence Tumenta, Carmen Black, and Joao P. DeAquino: “What Would Equitable Harm Reduction Look Like?”
Dr Elizabeth Salisbury-Afshar joins Ethics Talk to discuss her article, coauthored with Drs Catherine J. Livingston and Ricky N. Bluthenthal: “How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder?”
Dr Kelly Gillespie joins Ethics Talk to discuss her article, coauthored with Dr Taleed El-Sabawi: “When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond?”
Dr Jim Withers and Dave Lettrich join Ethics talk to discuss how street outreach programs help mitigate harms of drug use among people experiencing homelessness.